1-3 of 3
Jens Uhlig
Close
Sort by
Journal Articles

Interim Results of the Observational Study Caro: Twice Weekly Carfilzomib Is a Convenient Treatment Option for Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

Wolfgang Knauf, Andreas Ammon, Jens Uhlig, Marie Merling, Hans-Juergen Hurtz, Corinne Vannier, Holger Schulz, Norbert Marschner, Tamara Riedt, PhD, Karin Potthoff
Journal: Blood
Blood (2018) 132 (Supplement 1): 5662.
https://doi.org/10.1182/blood-2018-99-117996
Published: 2018
Journal Articles

Treatment with Bendamustine, Thalidomide and Prednisolone (BPT) in Patients with Refractory or Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Phase I Clinical Trial.

Wolfram Poenisch, MD, Marta Rozanski, Hartmut Goldschmidt, MD, Franz-Albert Hoffmann, MD, Thomas Boldt, MD, Andreas Schwarzer, MD, Ute Ruffert, MD, Robert Rohrberg, MD, Elke Schwalbe, MD, Jens Uhlig, MD, Thomas Zehrfeld, MD, Veronika Schirmer, MD, Antje Haas, MD, Ute Kreibich, MD, Dietger Niederwieser, MD
Journal: Blood
Blood (2006) 108 (11): 3564.
https://doi.org/10.1182/blood.V108.11.3564.3564
Published: 2006
Journal Articles

Bendamustine in Combination with Thalidomide and Prednisolone (BPT) in Patients with Refractory or Relapsed Multiple Myeloma after Conventional Chemotherapy: Final Results of a Phase I Study.

Wolfram Poenisch, MD, Marta Rozanski, Sabine Leiblein, PhD, Hartmut Goldschmidt, MD, Franz A. Hoffmann, MD, Thomas Boldt, MD, Robert Rohrberg, MD, Elke Schwalbe, MD, Jens Uhlig, MD, Dietger Niederwieser, MD
Journal: Blood
Blood (2005) 106 (11): 5154.
https://doi.org/10.1182/blood.V106.11.5154.5154
Published: 2005